ArticleNature communications2026
Reinforced biotubes as readily available and regenerative vascular grafts.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
The increasing prevalence of cardiovascular diseases and haemodialysis access drive high clinical demand for vascular grafts. Bioinert synthetic and decellularized or cryopreserved artery grafts exhibit poor regeneration and associated complications. Here, we present an approach that combines in vivo bioengineering and decellularization to prepare polycaprolactone skeleton-reinforced biotubes (dPB), which demonstrate appropriate mechanical strength, anti-kinking properties, resistance to repeat puncture, and are compatible with long-term storage at 4 °C. The loose and porous microstructure and immunomodulatory bioactivity of dPB induce rapid recellularization and promote pro-regenerative M2 macrophage polarization, which together facilitate remodelling to native artery-like tissue. In porcine coronary artery bypass grafting, canine carotid artery replacements and arteriovenous grafting models, ovine-derived dPB show high patency without dilatation, calcification and intimal hyperplasia. In summary, dPB offer a readily available and pro-regenerative vascular graft with a broad application prospect for patients with unavailable autologous vessels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.